Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.12 ^USD	-1.75%		-5.88%	+41.24%

May. 09	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
May. 08	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	MT

Adaptimmune Therapeutics plc Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021

May 06, 2021 at 05:39 am EDT

Adaptimmune Therapeutics plc announced unaudited consolidated earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced revenue was USD 434,000 compared to USD 761,000 a year ago. Operating loss was USD 37,889,000 compared to USD 29,764,000 a year ago. Net loss attributable to ordinary shareholders was USD 37,763,000 compared to USD 28,167,000 a year ago. Basic and diluted loss per share was USD 0.04 compared to USD 0.04 a year ago.

Latest news about Adaptimmune Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 09	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	May. 07	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	May. 02	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	Apr. 23	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
Transcript : Adaptimmune Therapeutics plc - Analyst/Investor Day	Apr. 18
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
Adaptimmune Therapeutics Says Unit Gets Termination Notice for Strategic Collaboration With Genentech	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading	Mar. 22	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	Mar. 20	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Mar. 14	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
ADRs Close Lower, Immuron Ltd. Declines 17.1%	Mar. 11	DJ

Chart Adaptimmune Therapeutics plc

Duration

Period

More charts

Company Profile

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Companyâs most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Adaptimmune Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.12 USD

Average target price

3.5 USD

Spread / Average Target

+212.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADAPTIMMUNE THERAPEUTICS PLC	+41.24%	286M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs